Premium
Effect of pegylated interferon‐α‐2a treatment on mental health during recent hepatitis C virus infection
Author(s) -
Alavi Maryam,
Grebely Jason,
Matthews Gail V,
Petoumenos Kathy,
Yeung Barbara,
Day Carolyn,
Lloyd Andrew R,
Van Beek Ingrid,
Kaldor John M,
Hellard Margaret,
Dore Gregory J,
Haber Paul S
Publication year - 2012
Publication title -
journal of gastroenterology and hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.214
H-Index - 130
eISSN - 1440-1746
pISSN - 0815-9319
DOI - 10.1111/j.1440-1746.2011.07035.x
Subject(s) - medicine , ribavirin , depression (economics) , pegylated interferon , hepatitis c , odds ratio , hepatitis c virus , confidence interval , population , mental health , psychiatry , immunology , virus , environmental health , economics , macroeconomics
Background and Aim: Pegylated interferon (PEG‐IFN) treatment for hepatitis C virus (HCV) infection has neuropsychiatric side effects. Data on the effect of HCV treatment on mental health among injecting drug users (IDUs) are limited. We assessed mental health during treatment of recently acquired HCV, within a predominantly IDU population. Methods: Participants with HCV received PEG‐IFN‐α‐2a (180 µg/week) for 24 weeks; HCV/HIV received PEG‐IFN with ribavirin. Depression was assessed using the Mini‐International Neuropsychiatric Interview (MINI). Logistic regression was used to identify factors associated with depression at enrolment and during treatment. Also, the effect of depression prior to and during treatment on sustained virological response (SVR) was assessed. Results: Of 163 participants, 111 received treatment (HCV, n = 74; HCV/HIV, n = 37), with 76% ever reporting IDU. At enrolment, 16% had depression ( n = 25). In adjusted analysis, depression at enrolment occurred less often in participants full‐/part‐time employed (adjusted odds ratio [AOR] 0.23; 95% confidence interval [CI]: 0.06, 0.82, P = 0.023) and more often in recent IDUs (AOR 3.04; 95% CI: 1.19, 7.72, P = 0.019). During treatment, 35% ( n = 31) developed new‐onset depression. In adjusted analysis, poorer social functioning (higher score) was associated with new‐onset depression (score ≤ 9 vs score ≥ 17; OR 5.69; 95% CI: 1.61, 20.14, P = 0.007). SVR was similar among participants with and without depression at enrolment (60% vs 61%, P = 0.951) and in those with and without new‐onset depression (74% vs 63%, P = 0.293). Conclusions: Although depression at enrolment and during treatment was common among participants with recent HCV, neither influenced SVR. Participants with poor social functioning may be most at risk of developing depression during HCV therapy.